SC
TOVX icon

Steven Check’s Theriva Biologics TOVX Stock Holding History

Steven Check’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1
Closed -$18K – 68
2014
Q3 		$18K Hold
1
– – ﹤0.01% 66
2014
Q2 		$17K Buy
+1
New +$15.9K ﹤0.01% 59

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
RFC
Regions Financial Corp Birmingham, Alabama $16.8B AUM 26.68% 1-Year Est. Return

Steven Check's TOVX Position: Q4 2014 in Review

Steven Check sold out of Theriva Biologics (TOVX) in Q4 2014, closing a stake of 1 share — an estimated $18K sold.

Steven Check first reported a position in TOVX in Q2 2014 and held it in 2 quarters. The position peaked at $18K in Q3 2014. 29 funds tracked by Wall St. Rank hold TOVX as of Q4 2014.

  • Steven Check reported no remaining Theriva Biologics position as of Q4 2014 after selling out during the quarter.
  • Steven Check sold 1 Theriva Biologics share in Q4 2014, an estimated $18K.
  • Steven Check first reported a position in Theriva Biologics in Q2 2014 and held it in 2 quarters.
  • Steven Check's Theriva Biologics position peaked at $18K in Q3 2014.
  • 29 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2014.

Based on Check Capital Management's 13F filing for Q4 2014, filed 23 Jan 2015.